Today's Veterinary Practice

MAY-JUN 2018

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link:

Contents of this Issue


Page 52 of 87

INDICAT ION Galliprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs. © 2018 Eli Lilly and Company or its affiliates. Elanco and the diagonal bar logo are trademarks of Eli Lilly and Company or its affiliates. Galliprant is a registered trademark of Aratana Therapeutics, Inc. USCACGLP00080 PRESCRIBE GALLIPR A N T ® (gr apipr ant t ablet s) FROM T HE E ARLIES T DIAGNOSED S TAGES OF OS T EOAR T HRI T IS (OA ). Galliprant is a fi rst-in-class, non-COX-inhibiting prostaglandin receptor antagonist (PRA) that specifi cally acts on the EP4 receptor. Its mode of action targets OA pain and infl ammation while reducing the impact on GI, kidney and liver homeostasis. 1,2 It was well-tolerated by healthy dogs in a 9-month safety study at up to 15 times the recommended therapeutic dose. 2,3 Visit for more information about Galliprant. S TA R T S E E ING O S T E O A R T HR I T I S F R OM A DIF F E R E N T P E R S P E C T I V E

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - MAY-JUN 2018